Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
최신 재무제표(Form-10K)에 따르면, Champions Oncology Inc의 총 자산은 $0이며, 순손실입니다.
CSBR의 주요 재무 비율은 무엇인가요?
Champions Oncology Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Champions Oncology Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Champions Oncology Inc 주요 수익원은 Pharmacology Services이며, 최신 수익 발표에서 수익은 48,585,000입니다. 지역별로는 United States이 Champions Oncology Inc의 주요 시장이며, 수익은 56,944,000입니다.
Champions Oncology Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Champions Oncology Inc의 순손실은 $0입니다.